Invitation to presentation in connection with EQL Pharma's year-end report, fourth quarter, 2022/23
EQL Pharma AB (publ) will publish its year-end report for the fourth quarter, 2022/23, on Thursday, May 11th, before stock markets opening.
At 10.00 (CET) 11th May, the company will give a presentation via video conference. The presentation is aimed at shareholders and potential shareholders. CEO and President Axel Schörling presents and comments on the year-end report. After the presentation, there is an opportunity to ask questions for those who participate.
Use the following link to access the virtual meeting: https://tinyurl.com/ttvtm8rp
Date and time
May 11th, 2023, at 10.00 (CET) the presentation starts. Time required for presentation and subsequent question time is estimated at a maximum 1 hour.
Make sure you are able to attend the video conference by logging in shortly before the start of the conference.
For further information, please contact:
Axel Schörling, CEO & President EQL Pharma AB (publ)
Phone: +46 (0) 76 317 90 60
E-mail: axel.schorling@eqlpharma.com
Website: www.eqlpharma.com
EQL Pharma AB (publ) in short
EQL Pharma AB specializes in developing and selling niche pharmaceuticals. The company currently has more than 20 niche generics (ie generics with limited competition apart from the reference pharmaceutical) approved in the Nordic markets and a couple of originals. In addition to these, there is a significant pipeline of mainly niche generics for launch in 2023 and beyond. The business is currently entirely focused on prescription pharmaceuticals, including hospital products, in the Nordic region and in selected European markets. EQL Pharma AB conducts its operations in Lund and is listed on the Spotlight Stock Market. EQL Pharma AB conducts extensive development work in collaboration with leading contract manufacturers and pharmaceutical companies in the EU and Asia, among others.